Successful use of rituximab, an anti‐CD20 monoclonal antibody, to treat IgA nephropathy in a patient with recessive dystrophic epidermolysis bullosa

We describe the successful use of rituximab for the treatment of IgA nephropathy in a patient with recessive dystrophic epidermolysis bullosa. To our knowledge, this is the first reported case in the literature.

Saved in:

Bibliographic Details
Published in:	Clinical and experimental dermatology Vol. 47; no. 8; pp. 1588 - 1590
Main Authors:	Hunjan, Manrup Kaur, Bardhan, Ajoy, Harper, Natasha, Langman, Gerald, Ajayi, Bamidele, Suresh, Vijay, Heagerty, Adrian H. M.
Format:	Journal Article
Language:	English
Published:	England Oxford University Press 01-08-2022
Subjects:	CD20 antigen Dystrophic epidermolysis bullosa Epidermolysis bullosa IgA nephropathy Immunoglobulin A Immunotherapy Monoclonal antibodies Patients Rituximab
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	We describe the successful use of rituximab for the treatment of IgA nephropathy in a patient with recessive dystrophic epidermolysis bullosa. To our knowledge, this is the first reported case in the literature.
Bibliography:	Data availability: Not applicable. Conflict of interest: The authors declare that they have no conflict of interest. Funding: Not applicable. Ethics statement: Ethics approval not applicable. The patient provided informed consent for publication of their case details and images. SourceType-Other Sources-1 content type line 63 ObjectType-Correspondence-1
ISSN:	0307-6938 1365-2230
DOI:	10.1111/ced.15228